

CWS meeting 1st July 2022

program

8.30-9.30h CWS board meeting

10h Wellcome

10h-13h: Workshops for EpSSG-CWS Surgery & Radiotherapy working groups on standard treatment to FaR-RMS guidelines, new projects

Part 1: Future Molecular and Immunological Approaches in Soft Tissue Sarcoma: how to improve treatment in metastatic and relapsed disease?

Molecularbiology-Pathology-Genetic Approaches and Phase I/II Studies (K. Pajtler/ T. Grünewald)

10-12h

10.00 Project on Clinical and molecular characterization of PAX-FOXO1 negative alveolar Rhabdomyosarcoma (E. Koscielniak/ S. Stegmaier, K. Maaß/ K. Pajtler)

10.15 Molecular characterization of bone and soft-tissue Ewing sarcoma (and DSRCT) (T. Grünewald)

10.30 Planned Project on Molecular and clinical characterization of sarcomatous tumours of the CNS in children and adolescents (B. von Zezschwitz/ D. Capper)

10.40 Histone modification analysis of ES in comparison to other SMARCB1 deficient entities (P. Johann)

10.50 Liquid Biopsy ARMS (S. Stegmaier)

11.05 Liquid Biopsy ERMS (K. Maaß, K. Pajtler)

11.15 Functional personalized drug sensitivity profiling in the pediatric precision oncology program INFORM with a focus on sarcomas (I. Oehme)

11.25 Project on radiosensitivity (R. Imle)

11.35 Genetics of Rhabdomyosarcoma (GEORA) (G. Seitz, J. Schuhmacher)

11.45 Genetic predisposition in RMS and NRSTS (C. Kratz)

Metastatic disease: Past and New (Immunological) Approaches (M. Ebinger/E. Rettinger)

12-13.15h

12.00 Results of CWS-2007 HR study (E. Koscielniak, T. Klingebiel)

12.15 Treatment approaches on metastatic RMS: data on HSCT (U. Thiel)

12.25 Pediatric Patients with Stage IV Soft Tissue Sarcoma Significantly Benefit from Long Term Maintenance Therapy (L. Tramsen/ K. Bochennek)

12.40 Single center, open-label, phase I dose finding and safety study on the oncolytic adenovirus XVir-N.31 in combination with the CDK4/6 inhibitor ribociclib and the immune-checkpoint inhibitor pembrolizumab in patients with treatment-refractory sarcoma (XVIR-RIB-PEM) (S. Schober)

12.50 PerVision (C. Seitz/M. Ebinger)

13.00 CAR-Therapies (E. Rettinger/ Team Frankfurt)

13.15-14.00h Lunch break

Part 2: Revolution in Local treatment and Imaging in Soft Tissue Sarcoma

Surgery/ Radiotherapy (J.Fuchs/ B. Timmermann) Imaging (J. Schäfer)

14.00-15.30h

14.00 Results of the workshop on new projects and CWS surgical guidelines as appendix to FaR-RMS/ ERN guideline (J. Fuchs/ CWS surgical working group)

14.30 Diagnostic and management of LN involvement in children and adolescents with RMS (J. Gesche/ G. Seitz; to be confirmed)

14.45 Results of the workshop on new projects and CWS radiotherapy guidelines as appendix to FaR-RMS/ ERN guideline (B. Timmermann/ CWS radiotherapy working group)

15.15 PET MRI project update, update on analysis of CWS data (J. Schäfer/ CWS imaging working group, to be confirmed)

15.30-15.45 Coffee break

Part 3: NEW Trials on NRSTS and rare tumors (I. Brecht/ M. Sparber-Sauer)

15.45 Phase II Study on Pleuropulmonary Blastoma, update (K.-A. Schultz, COG)

16.00 REACH (S. Gatz, EpSSG)

16.15 DESMOVER (N. Corradini, EpSSG)

16.30 HEROES-AYA (S. Pfister)

FOCUS on NEXT CWS-EpSSG meeting: Young investigators (D. Schneider)

17.00 Relapse data on RMS patients: SoTiSaR (A. Heinz)

17.15 Projects and Analyses of Young Investigators, overview (D. Schneider)

17.30 **Farewell**

next meeting: Friday, 25th November 2022 in Stuttgart focus on projects of Young investigators/ European colleagues/ AYA

Summer meeting 8th-12th May 2023 in Valencia/ SIOPE

Winter meeting 2023 at Tübingen